Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL

BACKGROUND: Subgroups of patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) exhibit suboptimal outcomes after standard therapies, including oral kinase inhibitors. We and others have previously reported on the safety and efficacy of autologous CD19-targeted CAR T cells for...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:JCI Insight
Main Authors: Geyer, Mark B., Rivière, Isabelle, Sénéchal, Brigitte, Wang, Xiuyan, Wang, Yongzeng, Purdon, Terence J., Hsu, Meier, Devlin, Sean M., Palomba, M. Lia, Halton, Elizabeth, Bernal, Yvette, van Leeuwen, Dayenne G., Sadelain, Michel, Park, Jae H., Brentjens, Renier J.
Formato: Artigo
Idioma:Inglês
Publicado: American Society for Clinical Investigation 2019
Assuntos:
Clinical Medicine
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6538317/
https://ncbi.nlm.nih.gov/pubmed/30938714
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.122627
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares